Literature DB >> 8584035

Overlapping cis-acting elements located in the first intron of the gene for type I 3 beta-hydroxysteroid dehydrogenase modulate its transcriptional activity.

S L Guérin1, S Leclerc, H Verreault, F Labrie, V Luu-The.   

Abstract

High levels of expression for the gene encoding human type I 3 beta-hydroxysteroid dehydrogenase (3 beta-HSDI) have been detected in placenta and skin but not in adrenals, which, however, express high levels of type II 3 beta-HSD. In this study, we addressed the issue of whether the differential pattern of cell-specific expression for type I 3 beta-HSD can be explained by the differential utilization of cis-acting regulatory elements present in the 3 beta-HSDI gene regulatory sequences. Deletion analyses indicated that removal of intron 1 strongly impaired the transcriptional activity directed by the 3 beta-HSDI basal promoter. Consequently, we focused our attention to the characterization of the 128 base pair first intronic sequence from the 3 beta-HSDI gene. A single protected region, designated the 3 beta I-A element, was identified by DNase I footprinting. Gel mobility shift assays indicated that at least four nuclear proteins with distinct biochemical and binding properties possess the ability to bind the 3 beta I-A element to produce four DNA-protein complexes (R1 to R4). However, the one producing R1, a 37-kilodalton protein that has been found in both human choriocarcinoma JEG-3 and adrenal cortex adenocarcinoma SW13 cells, as well as in all tested tissue culture cells, clearly accounts for the major 3 beta I-A-binding species. Site-directed mutagenesis provided the evidence that the 3 beta I-A element acts positively on the 3 beta-HSD-I gene promoter-mediated transcriptional activity upon transient transfection of both JEG-3 and SW13 cells. No homology has been found between the 3 beta I-A element and target sequences for other known transcription factors. In addition, of the four proteins binding the 3 beta I-A element, that producing R2 was identified as the positive transcription factor Sp1, whereas the identity of the remaining factors is still unknown. This is consistent with the presence of an Sp1 motif overlapping the 3 beta I-A element in intron 1, therefore pointing toward an important function played by this particular region in 3 beta-HSDI basal, but not cell-specific, gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584035     DOI: 10.1210/mend.9.11.8584035

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  5 in total

1.  The effect of non-coding DNA variations on P53 and cMYC competitive inhibition at cis-overlapping motifs.

Authors:  Katherine Kin; Xi Chen; Manuel Gonzalez-Garay; Walid D Fakhouri
Journal:  Hum Mol Genet       Date:  2016-02-07       Impact factor: 6.150

2.  Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene.

Authors:  Johannes Häberle; Marvin B Moore; Nantaporn Haskins; Véronique Rüfenacht; Dariusz Rokicki; Estela Rubio-Gozalbo; Mendel Tuchman; Nicola Longo; Mark Yandell; Ashley Andrews; Nicholas AhMew; Ljubica Caldovic
Journal:  Hum Mutat       Date:  2021-09-24       Impact factor: 4.878

3.  Transcription enhancer factor-5 and a GATA-like protein determine placental-specific expression of the Type I human 3beta-hydroxysteroid dehydrogenase gene, HSD3B1.

Authors:  Lihong Peng; Yong Huang; Fan Jin; Shi-Wen Jiang; Anita H Payne
Journal:  Mol Endocrinol       Date:  2004-05-06

4.  A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate.

Authors:  Renee D Kalmbach; Silvina F Choumenkovitch; Aron P Troen; Paul F Jacques; Ralph D'Agostino; Jacob Selhub
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

5.  Proximal GATA-binding sites are essential for human HSD3B1 gene transcription in the placenta.

Authors:  Tsai-Chun Lai; Hsiao-Fang Li; Yu-Shian Li; Pei-Yu Hung; Ming-Kwang Shyu; Meng-Chun Hu
Journal:  Sci Rep       Date:  2017-06-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.